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Introduction
It is widely accepted that cell-mediated immune functions
(cytotoxicity, delayed-type hypersensitivity, etc.) decline
with age [1,2]. These age-associated immunological
changes render an individual more susceptible to infection
and possibly cancer, as well as to age-associated auto-
immune disorders; they may also contribute to
atherosclerosis and Alzheimer’s disease [3–5]. There is
still no clear consensus as to why cell-mediated immunity
declines with age. It is generally believed that age-related
immune deficiency develops coincident with the gradual
involution of the thymus gland and, consequently, that
thymic-related (T-cell) functions are the most profoundly
affected. It has recently been suggested that the alter-
ations observed with ageing are a reflection of an accumu-
lation of relatively inert memory T cells and a consequent
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Abstract
It is widely accepted that cell-mediated immune functions decline with age, rendering an individual
more susceptible to infection and possibly cancer, as well as to age-associated autoimmune diseases.
The exact causes of T-cell functional decline are not known. One possible cause could be the
development of defects in the transduction of mitogenic signals following TCR stimulation. This T-cell
hyporesponsiveness due to defects of signalling through the TCR either from healthy elderly subjects
or from individuals with autoimmune diseases such as rheumatoid arthritis or systemic lupus
erythematosus results in an impaired ability to mount efficient immune responses and to maintain
responsiveness to foreign antigens. This implies that a high proportion of autoreactive T cells might
accumulate either intrathymically or in the periphery. T-cell anergy and differential TCR signalling could
thus also be key players in the disruption of tolerance and the onset of autoimmune diseases. The
increasing number of the elderly may lead to an increase of clinically important autoimmune diseases.
We will review the signal transduction changes through the TCR–CD3 complex in T lymphocytes from
healthy elderly subjects, which result in a modification of the activation of transcription factors involved
in IL-2 gene expression leading to decreased IL-2 production. The putative contribution of altered
T-cell signalling with ageing in the development of autoimmune diseases will be also discussed.
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reduction of reactive naïve T cells [6,7]. Nevertheless,
none of these findings alone can explain satisfactorily the
decline of cell-mediated immunity with age.
The proliferation and clonal expansion of T lymphocytes is
mostly controlled by interactions between the cytokine IL-2
and its cellular receptor [8] following TCR ligation [9]. It is
now well accepted that the induction of IL-2 secretion
decreases with age in mice, in rats and in humans [10]. It
seems that such defects occur in the transduction of mito-
genic signals following TCR stimulation. Indeed, recent
studies suggest that alterations in, for example, tyrosine
kinase activity, intracellular free calcium, inositol phosphates,
protein kinase C (PKC), and so on, may all contribute to
changes in signal transduction with ageing [11–15].
Although the signalling machinery in T cells is extremely com-
plicated and many steps remain to be clarified, the age-
related change in T-cell signal transduction may be one of
the most important causes of cell-mediated immune
response decline with ageing. Thus, considering the
decrease of cell-mediated immune response with ageing
and the possibility that alterations in signal transduction may
be one of the causes, we will review the signal transduction
changes in T lymphocytes from healthy elderly subjects that
would translate into a modification of the activation of tran-
scription factors involved in IL-2 gene expression leading to
decreased IL-2 production. The putative contribution of the
altered T-cell signalling with ageing in the development of
autoimmune diseases will also be discussed.
TCR and costimulatory signalling pathways
First, we will briefly summarize the very complex signalling
events occurring during TCR-mediated T-cell activation,
which leads to a perfectly coordinated immune response
and is essential for understanding the age-related
changes that may later lead to deregulated immune
responses. Engagement of the TCR by antigen in the
context of the MHC [16] interacting with the clonotypic
portion of the TCR–CD3 complex as well as the CD4 or
CD8 subunits results in a rapid early cascade of intracellu-
lar signalling events. This cascade leads to activation of
cytoplasmic and nuclear factors that are necessary, but
not sufficient, for IL-2 gene transcription. This is referred to
collectively as signal I [17]. Additionally, CD28 and other
less well-investigated costimulatory pathways must be
activated to ensure a complete and efficacious T-cell acti-
vation, collectively designated signal II [18,19].
Once the TCR is effectively engaged, cytoplasmic protein
kinases (PTKs) are recruited, which have been demon-
strated to be tightly associated with different components of
the CD3 complex and other T-cell antigens (CD4, CD8).
The activation of the src-like cytoplasmic tyrosine kinases
(lck, fyn) leads to phosphorylation of a number of immuno-
receptor tyrosine-based activation motif (ITAM) containing
proteins including TCRζ [20], and this promotes the recruit-
ment of a syk family member protein kinase, zeta-associated
protein (ZAP)-70, and induces its activation [21]. Lck and
Fyn functions are also regulated by the tyrosine phos-
phatase CD45, as well as by some recently identified phos-
phatase complexes [22]. Activated ZAP-70 phosphorylates
the linker of activated T cells (LAT), one of the most impor-
tant T-cell adapter proteins [23]. LAT then becomes a scaf-
fold protein for the recruitment of multiple partners including
the adaptor proteins Gads and Grb2 and the enzymes of
phospholipid metabolism phosphatidylinositol-3 kinase and
PLCγ1 [24]. Whereas phosphatidylinositol-3 kinase creates
novel binding sites in the inner leaflet of the plasma mem-
brane for the recruitment of pleckstrin homology domain-
containing proteins, activated PLCγ1 generates InsP3,
which is responsible for the mobilization of Ca2+ [25].
LAT-mediated recruitment of the Grb2–Sos complex to the
membrane initiates Ras activation. The GTP-bound p21ras
interacts with the serine/threonine kinase Raf-1, leading to
the activation of mitogen-activated protein kinases
(MAPKs). There are actually three MAPK subfamilies: extra-
cellular signal-regulated kinases (ERK1 and ERK2), p38
and JN kinases. The downstream signalling pathways medi-
ated by MAPKs are considered essential for normal cell
growth and proliferation [26]. PKC activation contributes to
the activation of MAPK, most probably via c-Raf-1 activa-
tion. Activated MAPKs can phosphorylate, at least in vitro,
a variety of transcription factors including c-jun, c-myc,
c-fos and p62TCF (Elk-1). The rise in intracellular calcium
activates the calcium/calmodulin-dependent serine/threo-
nine kinases and phosphatases, such as calcineurin, which
allows the cytoplasmic component of nuclear factors to be
activated and to move to the nucleus [27]. For instance,
NF-ATp will combine with newly formed Fra-1 (a member
of the fos family) and JunB proteins (induced by the PKC
pathway) to create the nuclear factor of activated T cell
(NFAT) complex. Finally, it has been shown that TCR-medi-
ated signal transduction causes the dissociation of the NF-
κB transcription factor from the inhibitory factor IkB,
probably via PKCθ-dependent phosphorylation of IkB [28].
LAT-associated Gads bring SLP-76 to the plasma mem-
brane where it becomes phosphorylated, allowing its inter-
actions with the exchange factor Vav, the adaptor proteins
Nck and SLAP-130/Fyb, and the tec PTK Itk. Vav and
SLAP-130/Fyb provide a link between T-cell activation,
upregulation of integrin affinity/avidity as a result of inside-
out signalling, and reorganization of the cell cytoskeleton
[29]. The TCR ligation-initiated complex and the interac-
tive signal transduction pathways thus lead to T-cell acti-
vation, resulting in differentiation, IL-2 production, clonal
expansion, survival and effectors functions. Although the
engagement of the TCR provides an essential signal to
T cells, commitment to proliferation, to differentiation and
to survival will not occur unless a secondary signal is pro-
vided by ligation of, for example, CD28 [30,31].292
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Although the pathways are still not fully established, sig-
nalling through CD28 is associated with phosphatidylinos-
itol-3 kinase that may involve activation of AkT/PkB and
other kinases. Phosphatidylinositol-3 kinase could be a
potent activator of the Ca2+-independent PKC, and its iso-
forms. Regardless, CD28 costimulation is essential for JN
kinase and NF-κB activation, which are necessary for acti-
vation of the IL-2 promoter [30]. CD28 thus contributes to
the overall increase of the efficacy of TCR signalling at mul-
tiple levels. Moreover, it has recently become evident that
CD28 assists in the assembly of the cytoskeleton and the
recruitment of lipid rafts to the TCR immunological
synapse. CD28 thus controls a wide range of events in
naïve CD4+ T cells, including a decrease of the TCR sig-
nalling threshold. In contrast, the major effect of CD28 in
CD4+ memory T cells is to enhance the TCR response,
whereas its role in CD8+ T cells is less clearly defined. This
two-signal concept has particular relevance for under-
standing T-cell tolerance and age-associated changes.
Much progress has very recently been made in our com-
prehension of how all these different events and pathways
are spatially linked to form an optimal signalling complex.
The notion of the immune synapse has emerged and is
now widely accepted. This is an informational synapse that
relays information across a quasi-stable cell–cell junction
during TCR interactions with the MHC–peptide complex
[32]. A redistribution of the signalling components takes
place in two major compartments: central supramolecular
activation clusters enriched in TCR and CD28, and
peripheral supramolecular activation clusters containing
leukocyte functional antigen-1 and talin. Another major
advance in our understanding is the recognition of the
existence of special membrane domains called rafts, small
regions of detergent-resistant complexes in the membrane
[33] enriched in glycosphingolipids and cholesterol,
defined as a liquid-ordered phase in the membrane. Lck
and LAT are targeted with other signalling molecules,
including members of the Src PTK family, heterotrimeric G
proteins and Ras, to glycolipid-enriched microdomains as
a consequence of post-translational palmitoylation [34].
After TCR ligation, phosphorylated TCR, ZAP-70, Shc and
PLC also localize to these microdomains. The inducible
assembly of signalling complexes within these
microdomains is a prerequisite for efficient TCR signal
transduction [35]. CD28, CD2, CD5 and lymphocyte
function-associated antigen-1 play a major role in recruit-
ing lipid rafts to the TCR synapse. It is of note that recent
studies indicate that Lck and LAT are present in different
lipid rafts [36]. The combination of these signalling events
results in the formation/activation of transcription factors.
The formation of the TCR synapse and the supramolecular
activation clusters provide a stable arrangement through
which the TCR can establish an optimal threshold for
complete T-cell activation. This threshold is dependent on
an optimal number and avidity of TCR–MHC peptide inter-
actions [16]. The cumulative effect of integrated signalling
events is to deliver a high fidelity signal that leads to T-cell
activation manifesting as proliferation, differentiation,
apoptosis, anergy, and/or development of memory or
effector functions, all modulated by the relative propor-
tions of T-cell subpopulations, costimulatory receptors,
membrane composition, type of antigen-presenting cell
(APC) or cytokine balance. When there is a disruption in
this fully integrated signalling cascade by changes occur-
ring either physiologically (including ageing) or pathologi-
cally (including cancer and autoimmune disease), this
leads to an altered immune response.
TCR and costimulatory signalling changes
with ageing: a biochemical paradigm for the
ageing immune system
It is well accepted that the early signalling events during
stimulation via the TCR–CD3 complex are altered with
ageing in T lymphocytes [11,14], as is the subsequent
expression of early-activation surface markers such as
CD69 and CD71 [37]. These changes might arise from
decreased numbers of TCR per cell or changed TCR re-
expression after stimulation, from alterations to the cell
membrane, from changes in the TCR signalling pathways
or from alterations of coreceptors.
Receptor number
A question that is still not completely settled is whether
the TCR receptor number does change with ageing. This
could be due to a decrease of expression or re-expression
of TCR. In T lymphocytes, experimental data show various
changes in TCR receptor number, but the bulk of the
experimental evidence suggests that with normal ageing
the TCR number does not change significantly [38].
However, TCR re-expression could be altered as a conse-
quence of the alteration in CD28 and its signalling.
Indeed, experimental data clearly show that the expression
of CD28 is decreasing with ageing [39].
Plasma membrane and lipid rafts of T cells
Specificity and fidelity of signal transduction are crucial for
cells to respond efficiently to changes in their environment.
This is achieved in part by the differential localization of pro-
teins that participate in signalling pathways. The lipid bilayer
of the plasma membrane is organized into cholesterol and
glycosphingolipid-rich microdomains, also called rafts
[40,41]. It was recently shown that TCR ligation induces a
redistribution of tyrosine-phosphorylated proteins into lipid
rafts. Experimental data collectively indicate that the plasma
membrane, via its special organization in lipid rafts, plays an
important role in signal transduction via the TCR [35]. It has
been known for some time, however, that there is an alter-
ation in the physicochemical status of the plasma mem-
brane, leading to increased rigidity and decreased fluidity
with ageing [42]. This may well affect raft formation [43].293
What is our actual knowledge concerning changes to
these immune synapses and lipid rafts with ageing? Very
limited information exists concerning this issue in the
context of TCR signalling. Miller and colleagues [44,45]
recently demonstrated an alteration in several components
of this signalling complex with ageing in memory T cells
[44] as well as in naïve T cells [45]. The most important
findings concern the reduced activation of several raft-
associated or recruited proteins, such as LAT, PKC, and
Vav in T cells of aged mice. There was an age-associated
decline in the proportion of CD4+ T cells that redistributed
LAT and Vav to the T cell–APC synapse upon ligation of
the TCR. Similarly, but at the level of the nucleus, the tran-
scription factor NF-ATc had a decreased redistribution
upon stimulation. Most probably the decreased recruit-
ment of the signalling molecules to the synapses is
responsible for decreased NF-ATc translocation to the
nucleus, playing a role in decreased IL-2 gene expression
[46]. The reasons for this altered tyrosine phosphorylation-
mediated activation are not yet known. Together, these
data show that alterations in the immune synapses and
lipid rafts can be found in both naïve cells and memory
cells with ageing. How all these affect the distinct func-
tioning of the cells will be the target of future research.
We ourselves were also interested to investigate in human
T cells whether the alteration of the cholesterol content of
the cell membrane, and in consequence that of lipid rafts,
could modulate the activation of various signalling path-
ways and functions [47]. In agreement with previous find-
ings, it was confirmed that the cholesterol content of the
T-cell plasma membrane was significantly increased with
ageing, which could explain its increasing rigidity with age
[15]. We recently found that the higher levels of choles-
terol were contained in lipid rafts (fractions 1–3) of T-cell
lysates that were more than twofold higher in the case of
elderly donors as compared with young donors (unpub-
lished data). Higher concentrations of cholesterol in heavy
sucrose density fractions (fractions 4–9) were also
observed. Why the levels of cholesterol are increased in
detergent-resistant microdomains (DRMs) from elderly
normolipidaemic individuals is not known. These results
may suggest, however, that the cellular regulation of cho-
lesterol metabolism is altered with ageing and could either
involve abnormal regulation of cellular cholesterol export
or altered production intracellularly [43,48].
Ageing has been reported to be associated with a
decrease in the fluidity of the T-cell plasma membrane
[49]. This alteration in physicochemical properties could
affect the formation of DRMs and their lateral mobility as a
result of the high levels of plasma membrane cholesterol.
Indeed, T cells exposed to anti-CD3 or a combination of
anti-CD3 and anti-CD28 mAb induced significantly
decreased raft coalescence in T cells of elderly subjects
independent of the stimuli used. The observed decrease in
DRM movement in the membrane bilayer may contribute
to the defects in T-cell proliferation seen with ageing [50]
as plasma membrane fluidity is needed for optimal T-cell
interactions with APCs [51]. The combination of anti-CD3
and anti-CD28 mAb was twice as effective as the anti-
CD3 mAb in triggering the coalescence of fluorescence.
These observations are in agreement with the findings of
Viola and colleagues [52], who showed that simultaneous
cross-linking of the TCR complex and CD28 was needed
to induce coalescence of lipid rafts in human T cells.
TCR ligation also induces a redistribution of tyrosine-
phosphorylated proteins into lipid rafts that include the
TCR components, phospholipase C, GRB2, ZAP-70 and
Lck [53]. A decline in the levels of tyrosine-phosphorylated
proteins following the activation of T cells from aged
humans [12] or from mice [54] has been reported and
these differences could be reflected in a differential distri-
bution in DRMs [55]. Our data show that the activation of
T cells resulted in an increase of pLck levels in DRMs of
young subjects, but not of elderly subjects.
LAT is an essential component of the assembly machinery
of signal transduction in T lymphocytes [56]. Activation of
T lymphocytes from young and old subjects results in
marked differences in DRM recruitment of LAT. Although
the bulk of the protein remained associated with the heavy
fractions, its relative distribution was more than fourfold
increased in DRMs of young individuals. This was not the
case in DRM fractions of T-cell lysates from elderly sub-
jects. Analyses of the tyrosine-phosphorylated LAT (pLAT)
distribution in DRMs showed >10-fold increases in DRM-
associated pLAT in lysates of activated T cells from young
subjects (unpublished data). However, the relative
increase in the recruitment of pLAT to DRMs was much
lower in T-cell lysates from elderly individuals. These find-
ings are in agreement with those observed in the case of
T cells from aged mice [45], and they may explain the
defects in downstream pathways of T-cell activation with
ageing and the chronic inflammatory process associated
with ageing [57]. These data reveal significant alterations
in the properties of DRMs with ageing, which include an
increase in cholesterol content, impaired DRM coales-
cence and selective differences in the recruitment of key
proteins involved in T-cell signalling (see Fig.1).
We have explored the effects of a cholesterol-extracting
molecule, methyl β-cyclodextrin, which is known to disrupt
rafts in T cells and, as a consequence, to alter signal trans-
duction upon TCR ligation [58]. Unlike other cholesterol-
binding agents that incorporate into membranes,
methyl-β-cyclodextrin is strictly surface-acting and selec-
tively extracts plasma membrane cholesterol [58]. It was
found that the effect of methyl-β-cyclodextrin was quite dif-
ferent on the cholesterol content and signalling molecules
of young subjects’ T lymphocytes versus elderly subjects’
Available online http://arthritis-research.com/content/5/6/290294
T lymphocytes. Extraction of cholesterol in T cells of young
healthy subjects had a very dramatic signal-disrupting
effect, while in T cells of healthy elderly subjects Lck,
ERK1 and ERK2 phosphorylations were enhanced com-
pared with the nontreated T cells. Proliferation of these
cells was also improved, although without attaining the
level of young subjects. These data further support an
alteration at the level of the lipid rafts and the idea that
membrane cholesterol plays a critical role in the homeo-
static regulation of signalling pathways in T cells [43,48],
which is altered with ageing. The manipulation of choles-
terol content might thus have an immunomodulating effect.
There is still much to be learned in relation to this new
concept of immune signal transduction during TCR liga-
tion with ageing in different T-cell subpopulations.
In addition to the increase in cholesterol content, alter-
ations to the membranes of cells associated with ageing
could be due to oxidation by free radicals [59]. Oxidative
stress has been shown to damage cell membranes, alter-
ing in vitro binding activity of AP-1 (activating protein-1)
and suppressing in vitro concanavalin A-induced T-cell
proliferation and IL-2 production [60].
Several age-dependent signalling pathways show
alterations upon TCR ligation
As already mentioned, the first step in TCR-mediated
signal transduction is the activation of different tyrosine
kinases, leading to the tyrosine phosphorylation of several
downstream proteins [61,62]. Several signalling pathways
were found altered with ageing either in experimental
animals or in humans. The level of tyrosine phosphoryla-
tion of p59fyn and ZAP-70 kinases is impaired in T cells
from old mice activated through the TCR–CD3 complex.
In human T cells, an age-related defect is observed in tyro-
sine-specific protein phosphorylation after activation via
TCR–CD3 complexes, CD4 and IL-2 receptors [63]. In
addition, a reduction in p59fyn activity was found in some
elderly subjects without compensation by p56lck activity.
We have also recently shown a substantial decrease in
p56lck activity in T lymphocytes of healthy elderly subjects
[15]. Consequently, as in mice, ZAP-70 activity is also
decreased in T cells. Not unexpectedly, there are some
discrepancies in the protein tyrosine kinase activity mea-
surement with ageing, but together these results suggest
that the activation and functions of the early signalling
protein tyrosine kinases induced by TCR ligation are
altered with ageing.
It is now well documented that other early events related
to protein tyrosine phosphorylation following TCR activa-
tion are altered with ageing, such as the generation of
myo-inositol 1,4,5-trisphosphate, intracellular free calcium
mobilization and PKC translocation [11]. Other studies, as
well as our own, concerning the changes in cytoplasmic
free calcium ion concentration as an index of the very early
events in the T-cell activation process, have shown that
the anti-CD3 mAb-induced mobilization of cytoplasmic
free Ca2+ declines with age [64,65]. There are some
studies concerning PKC activity with ageing in immune
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Figure 1
Schematic conceptualization of the changes with ageing in lipid raft composition following plasma membrane changes in cholesterol content and
their effects on early signalling events. LAT, linker of activated T cells; PKC, protein kinase C; TCR, T-cell receptor.295
cells. Proust and colleagues [65] have shown defects in
translocation of PKC in T lymphocytes of old mice. Our
own studies also demonstrated an altered PKC isozyme
distribution and translocation in human T lymphocytes with
ageing under anti-CD3 mAb stimulation. These alterations
in PKC activation might markedly contribute to the
observed impairment of T-cell activation with ageing.
Moreover, the results suggest that an inability to elevate
PKC activity after TCR stimulation may originate from
alterations in the early signal transduction events.
Only few data exist concerning phosphatase activity in
T cells with ageing. There is increasing experimental evi-
dence that the balance between tyrosine kinases and
phosphatases is essential for the maintenance of the
resting status and for activation [17]. CD45 is a receptor-
like protein tyrosine phosphatase expressed on all nucle-
ated haematopoietic cells. One key function of CD45 is to
serve as a positive regulator of src tyrosine kinases, by
opposing Csk function and by dephosphorylating the neg-
ative regulatory C-terminal tyrosine of src tyrosine kinases.
CD45-protein tyrosine phosphatase activity in old cells
after CD3 stimulation is not changed compared with that
in young cells [66]. No data exist thus far on changes of
activities of the other phosphatases with ageing. It can be
supposed, however, that the interaction between
Cbp/PAG (csk-binding protein/phosphoprotein associ-
ated with glycosphingolipid-enriched microdomain) and
Csk may be altered, and therefore the release of Csk
could also be altered. Further studies are needed in this
specialized field. These data together suggest that early
events in human T-cell activation are altered with ageing
(see Table 1).
Data are starting to accumulate showing that events more
distal from tyrosine kinases are also altered with ageing
[66]. Data indicate that the Ras-MAPK/ERK pathways are
also changed with ageing [67]. Whisler and colleagues
[68] have shown that 50% of old subjects had a reduction
in MAPK activation. ERK2 activation was correlated with
the ability of T cells to produce IL-2 and to proliferate.
Diminished ERK2 activation may thus represent one of the
rate-limiting steps for IL-2 production by T cells of old indi-
viduals. Furthermore, we have recently shown that there is
an alteration with ageing in MAPK/ERK as well as in p38
activation in T cells of the elderly compared with young
subjects following TCR stimulation [50], as already
demonstrated [69]. These data altogether suggest that an
alteration exits in the Ras-MAPK signalling pathway with
ageing, leading to decreased T-cell functions.
Transcription factor changes with ageing
The transcription factors studied to date show age-related
decreased activity. Data on the effect of age on the NFAT
complex show an age-related decline in NFAT binding to
nuclear extracts of T lymphocytes from rats [68]. The age-
related decline observed in NFAT binding activity could
arise through changes in its cytoplasmic component (i.e.
NFAT-p). A decrease in calcium signal generation with
age, through calcineurin, could then contribute to the
decreased NFAT binding activity as observed in nuclear
extracts isolated from splenocytes of old rats.
The other important transcription factor for IL-2 secretion
is NF-κB. This protein is constitutively expressed and
remains in the cytoplasm, bound to an inhibitory protein
IkB, prior to activation. When stimulated, T cells generate
reactive oxygen species, changing the redox status and
leading to phosphorylation and ubiquitination of IkB. This
results in dissociation of IkB from NF-κB followed by the
degradation of IkB by the proteasome. This in turn results
in the translocation of active NF-κB to the nucleus.
Studies on NF-κB showed a decrease in its activation in
mice and in humans mostly due to a decreased inactiva-
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Table 1
Signalling alterations occurring with ageing
Signalling alteration Role in T cells
Intracellular free Ca2+ Early T-cell activation
Myo-inositol Calcium release
1,4,5-trisphosphate production
Protein kinase C isoform T-cell activation
translocation
CD69 expression Activation surface marker
CD71 expression Activation surface marker
CD28 expression Costimulatory molecule
Membrane fluidity Protein trafficking
Cholesterol content Lipid rafts movement
Rafts-associated proteins Early T-cell activation, immune 
synapse formation
NF-AT distribution Calcium signalling
Regulation of cellular Molecule sorting, lipid rafts formation
cholesterol
Rafts coalescence T-cell activation, immune synapse
formation
Lck activation ZAP-70, ITAM phosphorylation
Linker of activated T cells Signalling platform
activation
Fyn activation ZAP-70, ITAM phosphorylation
ZAP-70 activation Linker of activated T cells activation
Extracellular signal- Late T-cell activation, proliferation
regulated kinase activation
p38 activation Late T-cell activation, proliferation
Proteasome activity NF-κB relocalization296
tion of IkB by the proteasomes [70]. Decreased protea-
some activity with ageing was also reported in tissues of
old rats and in cultured human fibroblasts undergoing
replicative senescence. The alteration of proteasome
activity with ageing was attributed to oxidative stress.
Based on these results, we conclude that ageing does
influence the activation of transcription factors following
T-cell stimulation, which may result in decreased IL-2 pro-
duction (see Table 1). However, more studies are needed
to elucidate the complete mechanism of this decline under
different experimental circumstances.
T-cell subpopulation changes with ageing
It is well known that the priming status of T lymphocytes
determines their response to stimulation as well as their
ultimate function. In this context the distinction between
naïve cells and memory cells becomes essential. Further-
more, important recent findings indicate that there is a dif-
ference between naïve and memory cells and effector cells
in terms of lipid raft distribution and protein content [71].
Naïve T cells have fewer rafts in their plasma membrane
and require CD28 costimulation to amplify TCR signalling
by recruiting rafts to the TCR-ligand contact site. By con-
trast, effector and/or memory T cells have more rafts in
their plasma membrane; amplification of signalling is thus
able to occur in the absence of CD28 costimulation.
It is generally quite well accepted that the number of
T cells does not change markedly with ageing. In contrast,
there is a consensus that ageing is accompanied by
changes in the proportions of T-cell subpopulations. There
is a higher number of T cells with the CD45RO+ ‘memory’
phenotype and much less with the CD45RA+ ‘naïve’ phe-
notype in peripheral blood mononuclear cells, although
this is of course an oversimplification, albeit a useful one
[7]. No matter which marker we use the numbers of naïve
cells dramatically decreases with ageing, mainly among
CD8+ cells. These alterations lead to decreased prolifera-
tive responses and to a decreased response to new anti-
gens, but possibly to a better response to antigens
already encountered.
CD28 may be considered a biomarker of ageing in T cells.
The proportion of CD28+ T cells decreases in vivo with
ageing and in in vitro culture models [72,73]. Effros
showed a decreased percentage of T lymphocytes that
are CD28+ in the CD8 T-cell subpopulation [7]. In addi-
tion, the average telomere lengths in the CD28– T cells
are decreased, indicating that these cells have undergone
numerous cell divisions. This type of proliferative senes-
cence might be responsible for the accumulation of oligo-
clonal CD28– populations in elderly subjects. Very few
data exist relating these changes in T-cell subpopulations
to the signal transduction changes observed in peripheral
blood lymphocytes. Some data seem to suggest that the
signal transduction changes demonstrated in the whole
population of T cells with ageing are also observed in iso-
lated naïve T cells [45]. However, several findings indicate
that the alterations rather reflect the behaviour of the accu-
mulated memory T cells with ageing. More in-depth analy-
ses are needed to establish the exact contribution of the
observed signal transduction changes, in the various T-cell
subpopulations, with ageing.
Other recently described T regulatory cells, such as
CD4+/CD25+ and natural killer T-cell subsets, could also
play an important role in ageing and in autoimmune dis-
eases such as diabetes mellitus type 1 [74]. It was shown
that these peripheral T-cell subsets actively contribute to
the maintenance of self-tolerance. What role these T-cell
subsets play in ageing is actually unknown. Future
research will certainly bring further information on these
cells, in relation to ageing, and help to integrate them into
the complicated network of T-cell subpopulations.
Putative contribution of TCR signalling
changes in ageing to the increase of
autoimmune disorders
The question arises as to why the risk of several diseases
having an autoimmune pathogenesis increases with age.
In fact, even though some autoimmune diseases occur in
childhood, others are typically related to ageing and often
develop after 50 years of age, such as rheumatoid arthritis
(RA) [75]. It is also of note that many alterations resem-
bling those found in autoimmune diseases, especially in
RA and in systemic lupus erythematosus (SLE) [19], exist
in healthy aged individuals, including an increase in
autoantibodies, a contraction in diversity of naïve T cells
with increased oligoclonality, an increase in memory
CD8+CD28– T cells, telomere shortening in T cells and
T-cell signal transduction alterations — albeit, however,
often without the appearance of overt autoimmune
disease [2].
Many aspects of the ageing immune system predispose to
the development of autoimmune diseases. Thymic involu-
tion has been evoked to be fundamental as this causes a
drastic decrease in naïve T cells and consequently leads
to the contraction in diversity of the T-cell repertoire.
During adulthood, the size of the peripheral T-cell pool is
maintained, consequent to the homeostatic proliferation of
peripheral T cells that also influences the T-cell repertoire
[76]. In fact, self-replication of naïve T  cells, driven by self-
antigens, is accelerated to help compensate for reduced
thymic output, and this could ultimately lead to clonal
expansion of cells with much higher affinity for self at the
expense of those that are weakly self-reactive but specific
for nominal antigen [75–77]. This process contributes to
physiological homeostasis by filling the unoccupied space
with phenotypically naïve cells lacking effector functions
[78]. In RA, however, these self-reactive T cells may
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acquire properties with potential for tissue injury resem-
bling those of certain senescent cells in the course of
ageing [79]. When lymphopaenia was induced in RA
patients aged older than 40 years, a similar phenomenon
was observed: the refilling of the space caused by
decreased thymic output of naïve T cells and the reper-
toire of peripheral T cells ultimately filling the space was
severely contracted [80]. These peripheral naïve T cells
underwent considerable proliferative activity indicated by
reduced telomere length.
Homeostatic proliferation is dependent on TCR triggering.
The two-signal model of T-cell activation has led to the
notion of T-cell anergy as a mechanism of maintenance of
tolerance in the periphery [18]. T-cell anergy was originally
described as the result of a lack of costimulation during
initial TCR engagement with antigen [19]. Although such
T-cell tolerance may represent a mechanism for peripheral
tolerance, it may also play a role in the development of
autoimmune diseases [81]. Indeed, in the absence of
either of these two signals T cells do not proliferate. It was
shown that an apparently diminished recruitment of Lck to
the TCR coupled with constitutively active Fyn may result
in the delivery of only partial signals to downstream events
in the T-cell activation pathway, and may lead to the
observed proliferative hyporesponsiveness of anergic
T cells [82,83]. In this context it is of note that, in contrast
to ageing and other autoimmune diseases, T cells from
patients with SLE display TCR-mediated signalling alter-
ations associated with defective TCR zeta chain expres-
sion [84] reconstitution, which restores IL-2 production
[85]. The maintenance of the anergic state is quite well
characterized, while the pathways inducing anergy are
largely unknown. In the maintenance of anergy in primary
T cells, impaired Ras activation seems to play a pivotal
role, which is in turn part of the defective TCR-mediated
signalling along the PKC-Ras-MAPK pathways [86]. This
correlates closely with the reduced activation and activity
of ERK2 MAPK that is required for progression to the
S phase of the cell cycle, thus explaining altered IL-2
secretion and proliferative hyporesponsiveness.
It is of interest that all these alterations were found with
ageing in naïve T cells as well as in memory T cells
[11,14], resulting in proliferative hyporesponsiveness
caused, in part, by an alteration of signal transduction
pathways, already described in detail. The pivotal PKC-
Ras-MAPK pathway, playing a role in anergy, is also
severely impaired with ageing. Moreover, the alteration of
the targeting of signalling molecules to the membrane with
ageing was also demonstrated for other molecules such
as PKC [64]. Recent results indicate that there is a
decrease in Lck expression in T-cell lipid rafts in patients
with SLE [36] and consequent alterations in intracellular
calcium mobilization and the tyrosine phosphorylation
pattern of cytosolic proteins. However, this could be inde-
pendent of TCR activation. Furthermore, the alteration in
the membrane composition and fluidity due to increased
cholesterol content could provide an explanation for these
signalling alterations [42,49].
The maintenance of anergy thus occurs through an altered
TCR signalling, mainly via PKC-Ras-MAPK pathways. This
anergy paradoxically may account for the breakdown of
the tolerance as seen in autoimmune diseases such as RA
as well as during the ageing process. In this scenario,
anergy of regulatory T cells, mainly of Th2 cells mediating
protection from autoimmune diseases [81], is postulated.
The hallmarks of this altered TCR activation upon ligation
are the increased levels of basal PTK activity, which corre-
late with the failure to upregulate PTK activity including
Lck and ZAP70, and a decrease in the induction calcium
mobilization (extracellular and intracellular) [86], suggest-
ing that the level of Src family tyrosine kinase activity is an
important determinant of immune tolerance (reviewed in
[87]). This altered signalling leads to a decrease in IL-2
and IL-4 production [88] with concomitant proliferative
hyporesponsiveness. It is then clear that cytokines play a
major role in regulating immune cells contributing to host
defence as well as to autoimmune diseases.
It is also well established that unregulated or changed
immune responses driven by cytokines contribute to the
pathogenesis of autoimmune diseases. For example, IL-6
knockout mice are totally resistant to collagen-induced
arthritis. In this connection, it is known that ageing is asso-
ciated with high IL-6 levels. Hence, the more we age, the
more we become sensitive to a variety of autoimmune-type
diseases. In addition to IL-6, other cytokine profile
changes occur with ageing. IL-2 is essential for T-cell pro-
liferation, and knocking out this cytokine and its various
receptor chains have been associated with the occur-
rence of autoimmune diseases in mice. It is of note that in
ageing, even if it is not associated with a complete lack of
IL-2 production (IL-2 ‘knockout’), the production of this
cytokine is commonly severely impaired. It could be then
suggested that autoimmune disease may be the clinical
manifestation of immunological dysregulation.
Moreover, IL-10 production has been shown to increase
with ageing, being part of the well-known Th1/Th2 imbal-
ance in favour of Th2 anti-inflammatory cytokines [2,6].
This could be one explanation for the increased incidence
of certain diseases with ageing and also, in part, an expla-
nation for many autoimmune diseases. However, this
needs further investigation. In fact, it has been demon-
strated that IL-10 derived from CD8+ T lymphocytes was
increased compared with IL-2 within the rheumatoid syn-
ovial membrane [89,90]. Hence, excessive IL-10 produc-
tion occurring with ageing may be involved in the
development of arthritis. It could appear paradoxical that
an anti-inflammatory cytokine like IL-10 can participate in
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the development of arthritis, but in ageing and in auto-
immune diseases there is a complete disequilibrium
between proinflammatory cytokines and anti-inflammatory
cytokines [2,6,90]. In fact, this altered cytokine balance can
explain that the increase of anti-inflammatory cytokines sup-
presses the specific immune response while it favours the
development of autoimmune phenomena. Whether IL-10
plays a role in the induction of autoimmune disease is still
unknown; we can, however, at least assume that it plays a
role in the maintenance of autoimmune diseases.
As mentioned earlier, cytokines are involved in the devel-
opment of autoimmune diseases. A family of molecules
involved in the inhibition of signalling has recently been
described [91], namely the suppressors of cytokine sig-
nalling. Whether these molecules (SOCS1–SOCS9) are
differentially expressed or whether a polymorphisms exists
with ageing is unknown, and further studies should be
carried out to determine the exact role of the suppressors
of cytokine signalling family in autoimmune disorders.
Once again, these alterations are not only seen in autoim-
mune diseases, such as diabetes type 1, SLE and RA
[88,92–94], but also in physiological ageing [11]. From
this point of view, autoimmune diseases could thus be
considered a model of premature ageing (see Fig.2).
Reciprocally, the decreased activation through the
TCR–CD3 complex and CD28-mediated costimulation
may render T cells from individuals with autoimmune
disease resistant to the induction of tolerance and activa-
tion-induced cell death (apoptosis) [95]. The diminished
ability of TCR stimulation to tolerate or eliminate autoreac-
tive T cells, which would normally be inactivated, may thus
lead to T-cell escape from negative selection by apoptosis
or functional anergy. It was also shown that the second
signal may be altered in autoimmune diseases as it is in
ageing. Impaired B7 expression on APCs and defects in
CD28/B7 costimulation also underlie abnormal T-cell acti-
vation in autoimmune diseases [96]. CD28 and a second
similar receptor, cytotoxic T leukocyte antigen-4, are posi-
tive and negative regulators of T-cell activation, respec-
tively. Cytotoxic T leukocyte antigen-4 is critical for the
induction of peripheral T-cell tolerance and for the deletion
of autoreactive T cells [97]. This family of costimulatory
molecules is ever expanding [98] and it was very recently
demonstrated that the inducible costimulator, the third
member of the CD28 family, was directly linked to arthritis.
Firstly, inducible costimulator-deficient mice exhibited
impaired immunoglobulin class-switching. Moreover, they
were very sensitive to experimental autoimmune
encephalomyelitis. Finally, inducible costimulator knockout
mice were completely resistant to RA [99].
A defect in costimulation may render T cells refractory to
TCR-mediated apoptosis or to tolerance-inducing signals.
The expansion of autoreactive T cells in the periphery may
thus result from the fact that the threshold required for
TCR activation is markedly increased for T cells in auto-
immune diseases. This leads to the already described
decreased signalling by PTK in autoimmune diseases
[81]. Moreover, the decreased recruitment of ZAP-70 to
membrane-bound TCRζ could also explain the decreased
susceptibility to apoptosis, because this intact association
is necessary for the upregulation of FasL on activated
T cells and consequently to AICD [100]. Thus, autoreac-
tive T cells that are unable to recruit and activate ZAP-70
cannot upregulate the FasL or cannot ultimately undergo
apoptosis via Fas/FasL interactions.
Studies suggest that TCR signalling abnormalities are not
restricted only to defective apoptosis, but that a cross-talk
exists between TCR and Fas for effective T-cell functions
[101]. Moreover, in autoimmune lymphoproliferative syn-
drome many patients display a dysregulated cytokine
pattern with dysfunctional T cells, suggesting that Fas
defects due to mutations may impact on pathways of
T-cell activation/differentiation. Goldman and colleagues
[102] reported the failure of CD4+ T cells from auto-
immune lymphoproliferative syndrome patients to upregu-
late surface activation markers including CD25 and CD69,
or to produce IFN-γ and IL-2 after CD3 stimulation. It is
thus suggested that a link exists between the Fas and
TCR signalling pathways. The link could be via MAPK
pathways, especially JN kinase [103]. This alteration in the
cross-talk between the Fas receptor and the TCR via
aberrant cytokine secretion may contribute to the develop-
ment and clinical manifestations of autoimmune diseases.
The role of these alterations in ageing and in other auto-
immune disorders is still unknown and awaits investiga-
tion. However, this could lead to improved understanding
of the complex relationships between regulation of sig-
nalling pathways and T-cell function (see Fig.2).
It has recently been shown that activation of the MAPK
pathway by T lymphocytes resulted in production of matrix
metalloproteinase (MMP-13) by osteoclasts in the context
of RA. Moreover, proinflammatory cytokines, including IL-1
and IL-17, synergize to induce the production of MMP-13
via activation of AP-1 (activating protein-1), explaining in
part bone loss and cartilage damage [104]. This bone
resorption in RA relates to the discovery of osteoclast-
mediated bone resorption that is regulated by receptor
activator of NF-κB ligand. This receptor is also present on
T cells and contributes under proinflammatory cytokine
stimulation to osteoclast maturation. Altered T-cell sig-
nalling thus leads to altered cytokine production, con-
tributing to the pathological hallmarks of RA in the joints
(reviewed in [105]). Furthermore, ageing is associated
with an increase of oxidative stress, explaining the
increased susceptibility to atherosclerosis and cardiovas-
cular diseases. Moreover, it has been proposed that oxida-
tive stress also alters proteins, and this seems to be
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another explanation for decreased signalling molecule
activation and activity. A role of protein oxidation in the ini-
tiation and/or progression of several diseases is indicated
by higher levels of oxidized proteins observed in tissues of
subjects with diseases such as Alzheimer’s disease,
Werner’s syndrome, and also RA [106]. Hence, the con-
sequences of oxidative stress observed with ageing are
also observed in diseases such as RA, contributing to
TCR signal transduction changes.
In summary, the alterations found in TCR signalling leading
to profound T-cell function changes with ageing, including
hyporesponsiveness, decreased tolerance and proneness
to apoptosis, may already be found in the early phases of
the development of autoimmune diseases such RA. Recip-
rocally, the alterations render aged individuals more sus-
ceptible to autoimmune diseases (see Fig.3).
Conclusion
T-cell hyporesponsiveness due to defects of signalling
through the TCR either from healthy elderly subjects or
from individuals with autoimmune diseases such as RA
and SLE results in an impaired ability to mount efficient
immune responses and to maintain responsiveness to
foreign antigens. This implies that a high proportion of
autoreactive T cells might accumulate either intrathymically
or in the periphery. T-cell anergy and differential TCR sig-
nalling could thus also be key players in the disruption of
tolerance and the onset of autoimmune diseases.
Although these studies are still in their infancy, data so far
suggest that alterations in TCR signalling and its regula-
tion can significantly contribute to the development of
autoimmune diseases. The increasing size of the elderly
population may lead to increases in clinically important
autoimmune diseases. It is thus imperative to better under-
stand the impact of TCR signalling changes with age on
susceptibility to autoimmune disease. This is the only way
to develop efficacious prevention and treatment for these
diseases. In this respect, further studies on the regulation
of cholesterol metabolism in aged T cells may help to
understand these signalling alterations and to better
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Figure 2
T-lymphocyte effector functions and signalling defects with ageing, role in autoimmune diseases. Defects in many activation pathways and
molecules lead to differential effects on T-cell behaviour, and thus on immune responses. Membrane reorganization, cytokine profiles, cellular
interactions, and T-cell subpopulation shifts are the consequences of the changes observed in T-cell signalling with ageing. The final consequence
is an increased susceptibility to disease that is accompanied by the development of a local environment of a sustained inflammatory state, critical
factors for the initiation, the development and the chronicity of autoimmune diseases. Abs, antibodies; AICD, activation-induced cell death; APC,
antigen-presenting cell; ARD, autoimmune renal disease; CTLA-4, cytotoxic T-leukocyte antigen-4; ECM, extracellular matrix; FBL, fibroblast; ICOS,
inducible costimulatory protein; IL-2R, IL-2 receptor; IP3, myo-inositol 1,4,5-trisphosphate; LAT, linker of activated T cells; MΦ, macrophage; MAP,
mitogen-activated protein; MMP, matrix metalloproteinase; PA, psoriasis arthritis; PKC, protein kinase C; RA, rheumatoid arthritis; SD, scleroderma;
SLE, systemic lupus erythematosus; TCR, T-cell receptor.300
define the role of DRMs in ageing and age-related dis-
eases. In addition, studies on T-cell subsets will help to
determine whether their responsiveness is selectively
affected in aged humans. Current investigations in our lab-
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